神经痛治疗市场－全球产业规模、份额、趋势、机会和预测，按治疗、适应症、配销通路、地区和竞争细分，2020-2030 年

2024 年全球神经痛治疗市场价值为 12.1 亿美元，预计在预测期内将实现令人瞩目的成长，到 2030 年的复合年增长率为 8.84%。 2023 年全球神经痛治疗市场的特征是神经痛相关疾病的诊断和管理显着增长和进步。全球神经痛治疗市场受到多种因素的驱动，例如神经系统疾病患病率上升、老年人口增加、药物开发进步、对疼痛管理认识的不断提高、医疗保健服务可及性的增强以及对三叉神经痛和带状疱疹后神经痛等慢性疼痛疾病的有效治疗需求不断增加。例如，2024 年 6 月，澳洲政府承诺从医学研究未来基金中拨款 1,960 万美元，用于改善初级医疗保健，并专注于慢性疼痛和多学科照护。 880 万美元将用于支持慢性疼痛治疗​​项目，重点关注农村社区并调整计划以减少残疾，提高医疗保健的可近性和疗效。

主要市场驱动因素

神经痛相关疾病盛行率上升

主要市场挑战

漏诊及误诊

主要市场趋势

进阶诊断工具

目录

第 1 章：产品概述

第二章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球神经痛治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗方法（药物治疗、手术治疗）
  • 依适应症分类（糖尿病神经病变、肋间神经痛、枕神经痛、週边神经痛、带状疱疹后神经痛、三叉神经痛）
  • 按配销通路（医院药房、网路药房、零售药房）
  • 按地区
  • 按公司分类（2024）
• 产品市场图
  • 按治疗
  • 按适应症
  • 按配销通路
  • 按地区

第 6 章：北美神经痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第七章：欧洲神经痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 法国
  • 义大利
  • 西班牙

第八章：亚太神经痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 日本
  • 印度
  • 澳洲
  • 韩国

第九章：南美神经痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲神经痛治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 科威特

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 合併与收购
• 产品发布

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• GSK PLC
• Pfizer Inc
• Novartis AG
• Biogen Inc
• Cadila Pharmaceuticals Ltd
• Lundbeck Pharmaceuticals Ltd
• Zydus Group (Cadila Healthcare Limited)
• Eli Lily and Company
• Allergan Inc.
• Baxter International Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

Global Neuralgia Treatment Market was valued at USD 1.21 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.84% through 2030. The Global Neuralgia Treatment Market in 2023 is characterized by significant growth and advancements in the diagnosis and management of neuralgia-related conditions.The global neuralgia treatment market is driven by factors such as the rising prevalence of neurological disorders, increasing geriatric population, advancements in drug development, growing awareness about pain management, enhanced healthcare access, and the rising demand for effective treatments for chronic pain conditions like trigeminal neuralgia and postherpetic neuralgia. For instance, in June 2024, the Australian Government committed USD 19.6 million from the Medical Research Future Fund to improve primary healthcare, emphasizing chronic pain and multidisciplinary care. USD 8.8 million will support chronic pain initiatives, focusing on rural communities and adapting programs to reduce disability, enhancing healthcare access and outcomes.

Key Market Drivers

Rising Prevalence of Neuralgia-Related Conditions

Neuralgia, a condition characterized by excruciating pain along nerve pathways, affects millions of individuals worldwide, significantly impacting their quality of life. While neuralgia encompasses various forms, including trigeminal neuralgia, postherpetic neuralgia, and diabetic neuropathy, one common trend is the rising prevalence of neuralgia-related conditions. This growing prevalence represents both a significant challenge and an opportunity for the healthcare industry. According to a 2024 Multiple Sclerosis (MS) Society study, over 150,000 people in the UK are living with multiple sclerosis (MS), with the increase attributed to improved diagnoses and longer life expectancies rather than a higher risk. The regional prevalence is: around 123,000 in England (1 in 450), 6,100 in Wales (1 in 500), 5,300 in Northern Ireland (1 in 350), and 17,400 in Scotland (1 in 300). Annually, more than 7,100 new cases are diagnosed, which averages to about 135 weekly.

Key Market Challenges

Underdiagnosis and Misdiagnosis

A major challenge is the underdiagnosis and misdiagnosis of neuralgia-related conditions. Many individuals endure their symptoms without seeking medical attention, often because they are unaware of their condition or its severity. Misdiagnosis can lead to inappropriate treatments and delays in receiving proper care.

Key Market Trends

Advanced Diagnostic Tools

Early and accurate diagnosis is crucial for effective neuralgia treatment. The development of more sophisticated diagnostic tools, such as high-resolution imaging, nerve conduction studies, and genetic testing, will enable healthcare professionals to identify neuralgia-related conditions with greater precision. Timely diagnosis will lead to more targeted treatments.

Key Market Players

• GSK PLC
• Pfizer Inc
• Novartis AG
• Biogen Inc
• Cadila Pharmaceuticals Ltd
• Lundbeck Pharmaceuticals Ltd
• Zydus Group (Cadila Healthcare Limited)
• Eli Lily and Company
• Allergan Inc.
• Baxter International Inc.

Report Scope:

In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuralgia Treatment Market, By Treatment:

• Drug-Based
• Surgery

Neuralgia Treatment Market, By Indication:

• Diabetic Neuropathy
• Intercostal Neuralgia
• Occipital Neuralgia
• Peripheral Neuralgia
• Postherpetic Neuralgia
• Trigeminal Neuralgia

Neuralgia Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Neuralgia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market.

Available Customizations:

Global Neuralgia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuralgia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Drug-Based, Surgery)
  • 5.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Treatment
  • 5.3.2. By Indication
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Neuralgia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Drug-Based, Surgery)
  • 6.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neuralgia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Neuralgia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Neuralgia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Neuralgia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment (Drug-Based, Surgery)
  • 7.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neuralgia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Neuralgia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France Neuralgia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Neuralgia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Neuralgia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Neuralgia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment (Drug-Based, Surgery)
  • 8.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Neuralgia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan Neuralgia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India Neuralgia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia Neuralgia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea Neuralgia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Distribution Channel

9. South America Neuralgia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment (Drug-Based, Surgery)
  • 9.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neuralgia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Neuralgia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Neuralgia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Neuralgia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment (Drug-Based, Surgery)
  • 10.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neuralgia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Neuralgia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Neuralgia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait Neuralgia Treatment Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Treatment
      • 10.3.4.2.2. By Indication
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. GSK PLC
• 14.2. Pfizer Inc
• 14.3. Novartis AG
• 14.4. Biogen Inc
• 14.5. Cadila Pharmaceuticals Ltd
• 14.6. Lundbeck Pharmaceuticals Ltd
• 14.7. Zydus Group (Cadila Healthcare Limited)
• 14.8. Eli Lily and Company
• 14.9. Allergan Inc.
• 14.10. Baxter International Inc.

15. Strategic Recommendations

16. About Us & Disclaimer